Provided by Tiger Trade Technology Pte. Ltd.

Apogee Therapeutics

77.35
+1.852.45%
Post-market: 77.350.00000.00%16:10 EST
Volume:910.73K
Turnover:69.96M
Market Cap:5.28B
PE:-17.74
High:78.14
Open:75.77
Low:74.54
Close:75.50
52wk High:78.15
52wk Low:26.20
Shares:68.32M
Float Shares:47.47M
Volume Ratio:0.96
T/O Rate:1.92%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.3614
EPS(LYR):-3.3001
ROE:-38.41%
ROA:-25.26%
PB:9.01
PE(LYR):-23.44

Loading ...

Apogee Therapeutics Initiated at Overweight by Stephens & Co.

Dow Jones
·
Dec 17

Stephens Initiates Coverage on Apogee Therapeutics With Overweight Rating, $95 Price Target

MT Newswires Live
·
Dec 17

BUZZ-RBC says biotech sector's rebound has momentum, with intriguing opportunities for 2026

Reuters
·
Dec 17

U.S. RESEARCH ROUNDUP-Airbnb, Garrett Motion, Range Resources

Reuters
·
Dec 17

Apogee Therapeutics CEO Michael Henderson Reports Sale of Common Shares

Reuters
·
Dec 13

Apogee Therapeutics Inc : Deutsche Bank Initiates Coverage With Buy Rating and Target Price $103

THOMSON REUTERS
·
Dec 10

U.S. RESEARCH ROUNDUP-JP Morgan, Pepsico, Pfizer

Reuters
·
Dec 10

Apogee Therapeutics Chief Medical Officer Carl Dambkowski Reports Sale of Common Shares

Reuters
·
Dec 06

Apogee Therapeutics CFO Jane Henderson Reports Disposal of Common Shares

Reuters
·
Dec 06

Does Positive APG333 Data and $345 Million Raise Redefine the Bull Case for Apogee Therapeutics (APGE)?

Simply Wall St.
·
Dec 03

Apogee Therapeutics CFO Jane Henderson Reports Disposal of Common Shares

Reuters
·
Nov 29

Positive Early APG333 Data Could Be a Game Changer for Apogee Therapeutics (APGE)

Simply Wall St.
·
Nov 23

Apogee Therapeutics CEO Michael Henderson Reports Disposal of Common Shares

Reuters
·
Nov 14

Apogee Therapeutics Reports Q3 2025 Financial Progress

TIPRANKS
·
Nov 12

RBC Capital Sticks to Their Buy Rating for Apogee Therapeutics (APGE)

TIPRANKS
·
Nov 12

Stock Track | Apogee Therapeutics Soars 5.28% Following Mizuho Securities' Bullish Stance

Stock Track
·
Nov 11

Stock Track | Apogee Therapeutics Soars 5.28% Following Mizuho Securities' Buy Rating and $105 Price Target

Stock Track
·
Nov 11

Mizuho Securities Sticks to Their Buy Rating for Apogee Therapeutics (APGE)

TIPRANKS
·
Nov 11

Apogee Therapeutics Reports Positive Interim Results for APG333 Antibody

MT Newswires Live
·
Nov 10

Positive Buy Rating for Apogee Therapeutics Driven by Promising Clinical Trials and Strategic Advancements

TIPRANKS
·
Nov 10